Professor Yingyao Chen is Professor of Health Technology Assessment at Fudan University School of Public Health, (FUSPH), Director of the National Health Commission Key Laboratory of Health Technology Assessment at Fudan University, and Director of World Health Organization (WHO) Collaborating Centre for Health Technology Assessment and Management, Shanghai, China. In addition, he is the Associate Dean of the FUSPH, responsible for international collaborations.
He received his Bachelor of Medicine and Master of Public Health at Shanghai Medical University in 1991 and 1997, respectively, and his PhD in Management at Fudan University in 2006. He took part in a visiting scholar programme at the University of California, Los Angeles from 1999 to 2001.
His academic interests focus on health technology assessment, health economics, hospital management and health policy. He was a principal investigator of projects funded by the WHO, World Bank, China Medical Board, National Health Commission (former Ministry of Health), Ministry of Science and Technology, National Medical Security Administration, National Natural Science Foundation of China (NSFC), and provincial health and health security authorities. He has published 200 papers (30 in English) as the first author and/or corresponding author. He is the editor-in-chief of Health Technology Assessment, Health Policy and Management, Hospital Human Resource Management, Evidence Based Health Care Decision and Management, Health Services Evaluation and Disease Burdens of Main Birth Defects and Economic Evaluation of Their Preventive Strategies in China. He was also one of core members to draft the Guideline for Health Technology Assessment in China.
He serves as the Vice-Chairman of the Public Health Economics Committee affiliated to China Health Economics Association, Chairman of the Health Technology Evaluation Committee of the China Medical Biotechnology Association, a standing committee member of Birth Defects Prevention and Management affiliated to Chinese Preventive Medicine Association and the group leader of health technology assessment and economic policy. He served as one of WHO Expert Members for Guideline on Country Pharmaceutical Pricing Policies, WHO TAG on Health Benefit Packages, the Co-Chair of the Cochrane China Network Executive Committee (2022), a member of board of directors of Health Technology Assessment international (HTAi) (2016-2019) and an observer at HTAi (2020).
His HTA research projects covered pharmaceuticals (such as immunotherapy, targeted drugs, anti-diabetes drugs, anti-hypertension drugs), medical devices (such as devices for paroxysmal atrial fibrillation, mitral regurgitation, robotic surgical system), equipment (such as CT, MRI), screening (such as for Down’s syndrome, thalassemia, neonatal genetic metabolic diseases, congenital heart diseases, HPV), clinical procedures (such as ozonated autohemotherapy, assisted reproductive technology), patient preference (people with lung cancer, diabetes, and mental health), knowledge translation (from HTA to macro-, meso-, and micro- policy making), HTA system development (international experiences and China practice).
He and his Fudan team organize China HTA Forum in the fall every year, which is a HTA platform for policymakers, academia, healthcare providers, NGOs, industry, and young students. He produced the first Chinese Massive Open Online Course (MOOC) in HTA (Chinese with English subtitles), which received the National Excellent MOOC Award, and promoted HTA knowledge among the Chinese audience.